AFFX Affymetrix, Inc.

The Affymetrix Microarray Bulletin (AMB) today published interviews with researchers from the University of Pennsylvania and the Scripps Research Institute who are using gene expression signatures to detect heart and kidney transplant rejection. Latest Headlines: -- Scientists Develop Noninvasive Method to Detect Organ Rejection in Heart Transplant Patients: U. Penn's Thomas Cappola and Johns Hopkins' Shui Ye discuss the future of using microarrays to detect heart transplant rejection without invasive biopsies. -- Researchers Discover Method to Diagnose Kidney Transplant Rejection Without Biopsy: Scripps' Daniel Salomon and Stanford's Michael Mindrinos discuss the advantage of using microarray analysis of blood samples to predict kidney transplant rejection and tailor immunosuppressive treatment. To view the complete stories, please visit: http://microarraybulletin.com/community About AMB: Affymetrix Microarray Bulletin (AMB) is a magazine published by Affymetrix, Inc. (Nasdaq:AFFX) that highlights leading microarray research and diagnostic developments around the world. AMB features interviews by and for scientists, statisticians and software engineers -- one expert interviewing another. Our goal is to create a forum where this community can discuss research and share new resources and information. For more information about AMB, please visit the publication's website at www.microarraybulletin.com About Affymetrix: Affymetrix scientists invented the world's first high-density microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,300 systems have been installed around the world and nearly 4,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif. with subsidiaries in Europe and Asia, as well as manufacturing facilities in Sacramento, Calif. and Bedford, Mass. The company has about 1,000 employees worldwide. For more information about Affymetrix, please visit the company's website at www.Affymetrix.com. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix Inc.